Background Lipid accumulation product (LAP) is an index calculated by waist circumference
(WC) and triglyceride (TG), which reflects lipid toxicity. This study aims to investigate the …

Non-alcoholic fatty liver disease (NAFLD) is a major cause of liver disease worldwide,
affecting up to 30% of adults. Progression to non-alcoholic steatohepatitis (NASH) is a key …

Background and Aims Liver disease remains a leading cause of morbidity and mortality
among people living with HIV (PLWH). Emerging data suggest that PLWH are at high risk for …

Simple Summary Using historical data from the Surveillance, Epidemiology, and End
Results database from 2001 to 2017, we were able to project the incidence of hepatobiliary …

Non-alcoholic fatty liver disease (NAFLD) is a global problem. It may be caused by
metabolic and hormonal disorders, including hypothyroidism. However, non-thyroid causes …

Hepatobiliary disorders are among the most common extraintestinal manifestations in
inflammatory bowel diseases (IBD), both in Crohn's disease and ulcerative colitis (UC), and …

Abstract Background In Australia, the overall prevalence of liver disease is increasing.
Maximising uptake of community screening programmes by understanding patient …

Metabolic-dysfunction-associated steatotic liver disease (MASLD) is becoming the most
common chronic liver disease worldwide and is of concern among African Americans (AA) in …

Non-alcoholic fatty liver disease (NAFLD) is a serious clinicopathological condition that is
recognized as the most frequent chronic liver disease, affecting 14–30% of the world's …

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as
nonalcoholic fatty liver disease (NAFLD), is increasing globally, creating a growing public …